AU2003253130A1 - Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders - Google Patents

Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders

Info

Publication number
AU2003253130A1
AU2003253130A1 AU2003253130A AU2003253130A AU2003253130A1 AU 2003253130 A1 AU2003253130 A1 AU 2003253130A1 AU 2003253130 A AU2003253130 A AU 2003253130A AU 2003253130 A AU2003253130 A AU 2003253130A AU 2003253130 A1 AU2003253130 A1 AU 2003253130A1
Authority
AU
Australia
Prior art keywords
pde
inflammatory
inhibitors
treatment
heterocyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003253130A
Other languages
English (en)
Inventor
Gopalan Balasubramanian
Laxmikant Atmaram Gharat
Usha Karunakaran
Aftab Dawoodbhai Lakdawala
V. S. Prasada Rao Lingam
Jitendra Raghunath Mohite
Abraham Thomas
Ruchi Verma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Pharmaceuticals Ltd
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AU2003253130A1 publication Critical patent/AU2003253130A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C07D239/76—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003253130A 2002-08-19 2003-08-19 Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders Abandoned AU2003253130A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN754MU2002 2002-08-19
IN754/MUM/2002 2002-08-19
PCT/IB2003/003364 WO2004016596A1 (fr) 2002-08-19 2003-08-19 Composes condenses heterocycliques utilises comme inhibiteurs de pde-iv dans le traitement de troubles inflammatoires et allergiques

Publications (1)

Publication Number Publication Date
AU2003253130A1 true AU2003253130A1 (en) 2004-03-03

Family

ID=31726529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003253130A Abandoned AU2003253130A1 (en) 2002-08-19 2003-08-19 Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders

Country Status (2)

Country Link
AU (1) AU2003253130A1 (fr)
WO (1) WO2004016596A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60317918T2 (de) 2002-10-23 2009-01-29 Glenmark Pharmaceuticals Ltd. Tricyclische verbindungen zur behandlung von entzündlichen und allergischen erkrankungen verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
BRPI0409747A (pt) 2003-04-11 2006-05-09 Glenmark Pharmaceuticals Sa novos compostos heterocìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo estes
MXPA06002521A (es) 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
MX2007004400A (es) 2004-10-13 2007-06-19 Glenmark Pharmaceuticals Sa Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida.
DK1831227T3 (da) 2004-12-17 2013-08-19 Glenmark Pharmaceuticals Sa Hidtil ukendte, heterocykliske forbindelser, der er anvendelige til behandling af inflammatoriske og allergiske forstyrrelser
WO2006064355A2 (fr) 2004-12-17 2006-06-22 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
CA2599376C (fr) * 2005-03-08 2014-05-13 Nycomed Gmbh Roflumilast pour le traitement du diabete sucre
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
MX2015009678A (es) * 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
EP2907806A1 (fr) 2014-02-14 2015-08-19 Universita Degli Studi Di Genova Nouveux composés comme inhibiteurs sélectifs de PDE4D

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3195352B2 (ja) * 1992-04-02 2001-08-06 スミスクライン・ビーチャム・コーポレイション アレルギーおよび炎症疾患の治療用化合物
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
WO1995009837A1 (fr) * 1993-10-01 1995-04-13 Smithkline Beecham Corporation Composes cyano
GB9404706D0 (en) * 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
WO2004016596A1 (fr) 2004-02-26

Similar Documents

Publication Publication Date Title
HK1111147A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
ZA200603221B (en) Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
AU2003263393A1 (en) New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
IL180205A0 (en) Quinazolin - 4 - yl - piperidine and cinnolin - 4 - yl - piperidine derivatives as pde10 inhibitors for the treatment of cns disorders
HK1082256A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
AU2003223380A1 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2003243318A1 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
SI1831227T1 (sl) Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
AU2003253130A1 (en) Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
AU2003210730A1 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
AU2003281479A1 (en) Use of polyisobutylene derivatives for treating metal surfaces
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
EP1575497A4 (fr) Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003285883A1 (en) Methods and compositions for determining risk of treatment toxicity
WO2004096848A8 (fr) Nouvelle composition et nouvelles methodes de traitement de troubles immunitaires

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase